NASDAQ: RAPT

Rapt Therapeutics Inc Stock Forecast, Predictions & Price Target

The consensus among 6 Wall Street analysts covering (NASDAQ: RAPT) stock is to Buy RAPT stock.

Out of 6 analysts, 1 (16.67%) are recommending RAPT as a Strong Buy, 2 (33.33%) are recommending RAPT as a Buy, 3 (50%) are recommending RAPT as a Hold, 0 (0%) are recommending RAPT as a Sell, and 0 (0%) are recommending RAPT as a Strong Sell.

If you're new to stock investing, here's how to buy Rapt Therapeutics stock.

(NASDAQ: RAPT) Rapt Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.08%.

Rapt Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast RAPT's revenue for 2026 to be $1,715,526,709, with the lowest RAPT revenue forecast at $1,715,526,709, and the highest RAPT revenue forecast at $1,715,526,709. On average, 1 Wall Street analysts forecast RAPT's revenue for 2027 to be $7,046,534,655, with the lowest RAPT revenue forecast at $7,046,534,655, and the highest RAPT revenue forecast at $7,046,534,655.

In 2028, RAPT is forecast to generate $10,842,963,943 in revenue, with the lowest revenue forecast at $10,842,963,943 and the highest revenue forecast at $10,842,963,943.

According to 6 Wall Street analysts that have issued a 1 year RAPT price target, the average RAPT price target is $21.00, with the highest RAPT stock price forecast at $41.00 and the lowest RAPT stock price forecast at $10.00.

On average, Wall Street analysts predict that Rapt Therapeutics's share price could reach $21.00 by Mar 27, 2025. The average Rapt Therapeutics stock price prediction forecasts a potential upside of 165.82% from the current RAPT share price of $7.90.

(NASDAQ: RAPT) forecast ROE is N/A, which is considered weak.